Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study
AsherBio
PPARG-High Circulating Monocytes Exhibit An Immunosuppressive Phenotype In Urothelial Cancer Patients Treated with Anti-PD1
AsherBio
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
AsherBio
PPARG Amplification is Associated with Lack of Response to Anti-PD1 in Muscle-Invasive Urothelial Cancer
AsherBio
AI Analysis of Histological Images Accurately Identifies Luminal Subtype Urothelial Carcinomas Characterized by High PPARG Expression
AsherBio
Development of a surrogate tissue pharmacodynamic (PD) assay for potential clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG)
AsherBio
Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models
AsherBio
Peroxisome proliferator-activated receptor gamma (PPARG) status defines the luminal lineage in molecular profiles of advanced urothelial cancers (UC)